Participation in Biotec Japan and local publicity activities on CARTISTEM2015/05/13STEM CELL THERAPEUTIC
The only Korean company invited to North American Rare Medicine conference2015/04/24STEM CELL THERAPEUTIC
Administration of lung disease medicine ‘PNEUMOSTEM’ in clinical trial completed2015/04/15STEM CELL THERAPEUTIC
Administration of lung disease medicine ‘PNEUMOSTEM’ started in U.S. clinical trial2015/03/25STEM CELL THERAPEUTIC
43% Increase in Dosage of CARTISTEM, for 4th Quarter of 2014 Year on Year2014/12/30STEM CELL THERAPEUTIC
Lung disease stem cell treatment drug ‘PNEUMOSTEM’ application for US clinical trial2014/08/12STEM CELL THERAPEUTIC
Lung disease stem cell drug designated ‘orphan drug in development stage’2014/07/29STEM CELL THERAPEUTIC
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022/12/01
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022/10/17
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products2022/05/31
